MaxCyte reports preliminary Q3 2025 revenue of $6.8M, down 16% YoY; reiterates FY2025 guidance

MAXCYTE, INC.

2025-Q3 EPS reported -$0.33 vs consensus -$0.11 ▼ miss (-194.1%)

Total revenue $6.8M, core revenue $6.4M (-21% YoY); adds three new SPL clients including Moonlight Bio.
Gross margin 77%; non-GAAP adjusted gross margin 81% (excl. SPL program revenue and inventory reserves).
Rescheduled Q3 earnings call to Nov 12, 2025 due to impairment testing of goodwill and long-lived assets; no prior quarter impact.
Cash and investments $158.0M at Sept 30, 2025; expects year-end cash $152-155M reflecting restructuring costs.
Reiterates FY2025 core revenue guidance: flat to -10% vs 2024; SPL program-related revenue ~$5M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.